TY  - JOUR
AU  - Rosiñol, Laura
AU  - Oriol, Albert
AU  - Rios, Rafael
AU  - Sureda, Anna
AU  - Blanchard, María Jesús
AU  - Hernández, Miguel Teodoro
AU  - Martínez-Martínez, Rafael
AU  - Moraleda, Jose M
AU  - Jarque, Isidro
AU  - Bargay, Juan
AU  - Gironella, Mercedes
AU  - de Arriba, Felipe
AU  - Palomera, Luis
AU  - González-Montes, Yolanda
AU  - Martí, Josep M
AU  - Krsnik, Isabel
AU  - Arguiñano, Jose M
AU  - González, Maria Esther
AU  - González, Ana Pilar
AU  - Casado, Luis Felipe
AU  - López-Anglada, Lucia
AU  - Paiva, Bruno
AU  - Mateos, Maria-Victoria
AU  - San Miguel, Jesus F
AU  - Lahuerta, Juan-José
AU  - Bladé, Joan
PY  - 2019
DO  - 10.1182/blood.2019000241
UR  - http://hdl.handle.net/10668/14471
T2  - Blood
AB  - Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) +...
LA  - en
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bortezomib
KW  - Chemotherapy, Adjuvant
KW  - Dexamethasone
KW  - Female
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Induction Chemotherapy
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Neoadjuvant Therapy
KW  - Transplantation Conditioning
KW  - Transplantation, Autologous
TI  - Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
TY  - research article
VL  - 134
ER  -